Objectives Cardiopulmonary involvement (CPI) is a major cause of morbidity and mortality in systemic sclerosis (SSc). The 6 min walk test (6MWT) is widely used to assess functional capacity, but its ...

Background Previous genome-wide association studies (GWAS) have identified numerous genetic loci associated with juvenile idiopathic arthritis (JIA). However, the functional impact of these ...

Jih- Jin Tsai, Li-Teh Liu, Chun-Hong Chen, et al. COVID-19 outcomes in patients with rheumatoid arthritis with biologic or targeted synthetic DMARDs. RMD Open 2023;9:e003038.

Background Rheumatoid arthritis (RA) poses a significant global health challenge. This study examined trends in the incidence, prevalence and mortality of RA from 1990 to 2021 at global, regional and ...

Objectives The impact of body mass index (BMI) on cardiovascular risk in rheumatoid arthritis (RA) is unclear. RA characteristics may influence the association between BMI and risk. Disease activity, ...

Inflammatory myopathies (IM) are a group of severe autoimmune diseases, sharing some similarities, whose cause is unknown and treatment is empirical. While C-protein-induced myositis (CIM), the most ...

Objective To analyse work participation among patients with inflammatory rheumatic musculoskeletal diseases (iRMDs), namely rheumatoid arthritis (RA), axial spondyloarthritis (axSpA), psoriatic ...

Introduction The study aimed to identify and describe disease activity trajectories over 10 years in patients with recent-onset axial spondyloarthritis (axSpA) and determine their impact on long-term ...

Correction: comparison of active tuberculosis occurrence associated with janus kinase inhibitors and biological DMARDs in rheumatoid arthritis ...

Background Janus kinase inhibitors are an effective option for achieving sustained remission or low disease activity in patients with rheumatoid arthritis (RA) following inadequate response to ...

Background The psoriatic arthritis (PsA) Observational Study of Persistence of Treatment (PRO-SPIRIT) assesses effectiveness and persistence of real-world PsA treatments. Ixekizumab (IXE) is an ...

Letter to the editor regarding non validated patient and radiofrequency technique for facet pain: re: Truong K. et al.